Company Growth (employees)
Merrimack Pharmaceuticals was founded in 2000 and is headquartered in Cambridge, US
Key People at Merrimack Pharmaceuticals
Richard Peters
President and Chief Executive Officer
Merrimack Pharmaceuticals Office Locations
Merrimack Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
1 Kendall Square
Merrimack Pharmaceuticals Data and Metrics
Merrimack Pharmaceuticals Financial Metrics
Merrimack Pharmaceuticals's revenue was reported to be $144.3 m in FY, 2016 which is a 62% increase from the previous period.
USD
Revenue (FY, 2016) | 144.3 m |
Revenue growth (FY, 2015 - FY, 2016), % | 62% |
Gross profit (FY, 2016) | 137.4 m |
Gross profit margin (FY, 2016), % | 95% |
Net income (FY, 2016) | (153.5 m) |
EBIT (FY, 2016) | (110.1 m) |
Market capitalization (21-Jul-2017) | 173.7 m |
Cash (31-Dec-2016) | 21.5 m |
EV | 369 m |
Merrimack Pharmaceuticals's current market capitalization is $173.7 m.
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Revenue | 47.8 m | 102.8 m | 89.3 m | 144.3 m |
Revenue growth, % | 115% | (13%) | 62% | |
Cost of goods sold | 6.9 m | |||
Gross profit | 89.2 m | 137.4 m | ||
Gross profit Margin, % | 100% | 95% | ||
R&D expense | 160.9 m | |||
General and administrative expense | 80.7 m | |||
Operating expense total | 218.8 m | 254.4 m | ||
EBIT | (120.5 m) | (66.3 m) | (129.6 m) | (110.1 m) |
EBIT margin, % | (252%) | (64%) | (145%) | (76%) |
Interest expense | 19.2 m | 43.6 m | ||
Interest income | 99 k | 276 k | ||
Net Income | (130.7 m) | (83.6 m) | (147.8 m) | (153.5 m) |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Cash | 65.1 m | 35.7 m | 185.6 m | 21.5 m |
Accounts Receivable | 5.9 m | 3.3 m | 6.5 m | 17.5 m |
Inventories | 5.5 m | 4.7 m | 5.5 m | 14.6 m |
Current Assets | 166.6 m | 132.1 m | 201.4 m | 57.4 m |
PP&E | 13.4 m | 14.5 m | 21.9 m | 15.8 m |
Goodwill | 3.6 m | 3.6 m | 3.6 m | 3.6 m |
Total Assets | 192.4 m | 158.7 m | 234.9 m | 81.5 m |
Total Debt | 216.9 m | |||
Current Liabilities | 57.7 m | 111.1 m | 103.7 m | 88.2 m |
Total Liabilities | 334.1 m | |||
Additional Paid-in Capital | 527.8 m | 552 m | 617.1 m | 702.4 m |
Retained Earnings | (572.2 m) | (655.2 m) | (802.2 m) | (954.8 m) |
Total Equity | (43.5 m) | (102.1 m) | (183.9 m) | |
Debt to Assets Ratio | 2.7 x | |||
Financial Leverage | -4.4 x | -1.6 x | -1.3 x |
| USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
|---|---|---|---|---|
Net Income | (130.7 m) | (83.6 m) | (147.8 m) | (153.5 m) |
Depreciation and Amortization | 2.6 m | 3.2 m | 4.3 m | 6.2 m |
Accounts Receivable | 3.4 m | 2.6 m | (3.2 m) | (11 m) |
Inventories | 4 m | 827 k | (850 k) | (9.7 m) |
Cash From Operating Activities | (95.2 m) | (34.8 m) | 149.9 m | (170.2 m) |
Purchases of PP&E | (9.9 m) | (6 m) | (12.8 m) | (3.2 m) |
Cash From Investing Activities | (27.7 m) | (6 m) | 75.1 m | (3.3 m) |
Cash From Financing Activities | 150.3 m | 11.4 m | 180.2 m | 9.4 m |
Interest Paid | 3.9 m | 9.5 m | 10.1 m | 23.9 m |
| USD | Y, 2016 |
|---|---|
EV/EBIT | -3.4 x |
EV/CFO | -2.2 x |
Revenue/Employee | 338.7 k |
Debt/Assets | 2.7 x |
Merrimack Pharmaceuticals Market Value History
Merrimack Pharmaceuticals Median Salaries
Source: 20 public H-1B filings from Merrimack Pharmaceuticals
